Payloads & linkers
The chemistry shared across the 99 ADCs, grouped by the 31 distinct payloads and 47 linker platforms. Each box gives the structure, key physicochemistry, and every ADC built on it - ranked by ocular burden, so you can see whether a shared payload gives consistent toxicity.
Monomethyl auristatin E (MMAE)
Auristatin · Microtubule polymerization inhibitor
28 ADCs19.4% mean ocular
MW
717.98 Da
logD₇.₄
2.9
charge
0
bystander
Yes
94.7DP-303cERBB266CRB-701 (SYS6002)NECTIN455Tisotumab vedotinF347Iladatuzumab vedotinCD79B47MYTX-011MET40Enfortumab vedotinNECTIN429Sirtratumab vedotinSLITRK627MRG-004AF325Telisotuzumab vedotinMET24.4Samrotamab vedotin (ABBV-085)LRRC1521.2SYSA-1801CLDN1820Lifastuzumab vedotinSLC34A210DLYE5953A (RG-7841)LY6E10JK-06TPBG9.5Pinatuzumab vedotinCD225.9BRY-812SLC39A65Brentuximab vedotinTNFRSF85Disitamab vedotinERBB21.2Polatuzumab vedotinCD79B0ATG-022CLDN180DMOT4039AMSLN0EBC-129CEACAM5; CEACAM60FOR-46CD460Glembatumumab vedotinGPNMB0Indusatumab vedotinGUCY2C0OBI-999-0TORL-1-23CLDN60Zilovertamab vedotinROR1
full details →
Cys-mcMMAF
Auristatin · Tubulin inhibitor
11 ADCs62.3% mean ocular
MW
1046.3 Da
logD₇.₄
-1
charge
-1
bystander
No
94Depatuxizumab mafodotinEGFR92Belantamab mafodotinTNFRSF1785AGS-16C3FENPP384Denintuzumab mafodotin (NHL)CD1957Vorsetuzumab mafodotinCD7056Denintuzumab mafodotin (ALL)CD1955.3FS-1502ERBB246.4ARX788ERBB246.3ARX-305CD7038.5PF-06263507TPBG31AGS-16M8FENPP3
full details →
DM4 (free)
Maytansinoid · Tubulin inhibitor
11 ADCs34% mean ocular
MW
780.4 Da
logD₇.₄
3
charge
0
bystander
Yes
59Mirvetuximab soravtansineFOLR156.3JBH-492CCR750Cantuzumab ravtansineMUC149Praluzatamab ravtansineALCAM38Tusamitamab ravtansineCEACAM537Anetumab ravtansineMSLN36SAR-566658MUC1 (CA6 epitope carried on MUC1)25Coltuximab ravtansineCD1912LY3076226 (IMC-D11)FGFR36.3Indatuximab ravtansineSDC15.9MEN-1309 (OBT076)LY75
full details →
SG3199 (PBD dimer)
PBD dimer · DNA cross-linker
5 ADCs11.6% mean ocular
MW
584.7 Da
logD₇.₄
2.5
charge
0
bystander
Partial
53.7MEDI2228TNFRSF172.9SC-002 (rovalpituzumab, DLL3, PBD/SG3199)DLL30.9Camidanlumab tesirineIL2RA0.54Rovalpituzumab tesirineDLL30Loncastuximab tesirineCD19
full details →
DM1 (mertansine / emtansine)
Maytansinoid · Microtubule inhibitor (tubulin polymerization inhibitor / anti-mitotic)
4 ADCs11.9% mean ocular
MW
738.3 Da
logD₇.₄
-
charge
0
bystander
No
Exatecan
Topoisomerase I inhibitor · DNA topoisomerase I (TOP1) inhibitor; membrane-permeable, strong bystander effect
4 ADCs0% mean ocular
MW
435.4 Da
logD₇.₄
-
charge
0
bystander
Yes
seco-DUBA (duocarmycin)
Duocarmycin · DNA minor-groove alkylation; seco-DUBA activated to DUBA causing irreversible DNA alkylation
3 ADCs32.6% mean ocular
MW
527 Da
logD₇.₄
-
charge
0
bystander
Yes
DXd
Topoisomerase I inhibitor · TopoI inhibitor
3 ADCs17.2% mean ocular
MW
493.5 Da
logD₇.₄
1.4
charge
+1
bystander
Yes
Aur0101 (auristatin 0101; PF-06380101)
Auristatin · Microtubule / tubulin-polymerization inhibitor (antimitotic)
3 ADCs7% mean ocular
MW
743 Da
logD₇.₄
-
charge
+1
bystander
-
Calicheamicin gamma1
Calicheamicin · DNA strand break
3 ADCs2.7% mean ocular
MW
1368.4 Da
logD₇.₄
2
charge
0
bystander
Partial
Duostatin-5
Auristatin · Tubulin inhibitor
2 ADCs80% mean ocular
MW
772 Da
logD₇.₄
3
charge
+1
bystander
-
ZD02044 (zovodotin)
Auristatin · Tubulin inhibitor (microtubule polymerization inhibitor)
2 ADCs43.5% mean ocular
MW
753 Da
logD₇.₄
-
charge
0
bystander
-
SGD-1882 (PBD dimer)
PBD dimer · DNA minor-groove interstrand crosslinker (alkylation) -> DNA damage, cell-cycle arrest, apoptosis
2 ADCs3.5% mean ocular
MW
725.8 Da
logD₇.₄
-
charge
0
bystander
Yes
DM21 (linker-payload DM21-C)
Maytansinoid · Microtubule inhibitor (tubulin polymerization inhibitor; antimitotic)
1 ADC77.8% mean ocular
MW
780.4 Da
logD₇.₄
-
charge
0
bystander
Yes
Auristatin F-HPA (AF-HPA)
Auristatin · Tubulin inhibitor (microtubule)
1 ADC41% mean ocular
MW
803.1 Da
logD₇.₄
-
charge
+1
bystander
Yes
Auristatin W
Auristatin · Tubulin inhibitor
1 ADC40% mean ocular
MW
746 Da
logD₇.₄
1.5
charge
Zwitterion
bystander
No
Maytansine (maytansinoid derivative; ADCdb PAY0CHGPD)
Maytansinoid · Microtubule/tubulin polymerization inhibitor (antimitotic, M-phase arrest)
1 ADC31% mean ocular
MW
650.17 Da
logD₇.₄
-
charge
0
bystander
No
Paclitaxel
Taxane · Microtubule stabilizer / tubulin inhibitor (antimitotic)
1 ADC10% mean ocular
MW
853.9 Da
logD₇.₄
-
charge
0
bystander
-
Tubulysin (proprietary tubulysin analog)
Tubulysin · Microtubule destabilizer; inhibits tubulin polymerization (binds vinca domain of beta-tubulin)
1 ADC10% mean ocular
MW
842.1 Da
logD₇.₄
-
charge
0
bystander
Yes
Eribulin
Microtubule (other) · Tubulin inhibitor
1 ADC9% mean ocular
MW
729.9 Da
logD₇.₄
-
charge
+1
bystander
Yes
n/a
PE38 (Pseudomonas exotoxin)
Other · ADP-ribosyl. eEF2 (protein)
1 ADC9% mean ocular
MW
38000 Da
logD₇.₄
-
charge
-
bystander
No
SN-38
Topoisomerase I inhibitor · TopoI inhibitor
1 ADC5% mean ocular
MW
392.4 Da
logD₇.₄
1.5
charge
0
bystander
Partial
Rezetecan (SHR9265 / SHR169265)
Topoisomerase I inhibitor · TopoI inhibitor
1 ADC3.3% mean ocular
MW
533.55 Da
logD₇.₄
1.89
charge
+1
bystander
Yes
KL610023 (also T030; belotecan-derived)
Topoisomerase I inhibitor · Topoisomerase I inhibitor (belotecan-derived camptothecin); arrests cell cycle at G2/S
1 ADC2.3% mean ocular
MW
511.6 Da
logD₇.₄
-
charge
0
bystander
Yes
IRDye700DX
Photosensitizer · Photochemical (690 nm NIR ROS)
1 ADC0% mean ocular
MW
1954.2 Da
logD₇.₄
-5
charge
-4
bystander
No
HDP 30.2115 (alpha-amanitin derivative)
Amatoxin · RNA polymerase II inhibitor (transcription inhibition; POLR2A poison)
1 ADC0% mean ocular
MW
919 Da
logD₇.₄
-
charge
-
bystander
Partial
N-acetyl-gamma-calicheamicin
Calicheamicin · DNA double-strand break induction (enediyne DNA-damaging agent)
1 ADC0% mean ocular
MW
1410.4 Da
logD₇.₄
-
charge
0
bystander
Partial
Maytansinoid (DM4-class maytansine derivative; warhead SC236)
Maytansinoid · Tubulin polymerization inhibition / microtubule disruption -> mitotic arrest -> apoptosis
1 ADC0% mean ocular
MW
794.4 Da
logD₇.₄
-
charge
0
bystander
Partial
Auristatin F-hydroxypropylamide (AF-HPA; ledadotin; DolaLock/Dolasynthen payload)
Auristatin · Microtubule polymerization inhibitor; AF-HPA is membrane-permeable and is intracellularly converted to the membrane-impermeable active catabolite auristatin F (controlled bystander effect)
1 ADC0% mean ocular
MW
803.1 Da
logD₇.₄
-
charge
0
bystander
Partial
YL0010014
Topoisomerase I inhibitor · DNA topoisomerase 1 (TOP1) inhibition
1 ADC0% mean ocular
MW
450.4 Da
logD₇.₄
-
charge
0
bystander
Yes